24/7 Market News Snapshot 08 July, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

July 8, 2025

DENVER, Colo., 08 July, 2025 (www.247marketnews.com) – (Nasdaq:PSTV) are discussed in this article.
Plus Therapeutics, Inc. (Nasdaq:PSTV) is experiencing significant momentum in pre-market trading, with shares soaring approximately 48% to $0.445, up from $0.300, fueled by a remarkable trading volume of 22.70 million shares. This surge reflects heightened investor interest as technical indicators suggest a bullish trend, positioning PSTV as a stock to closely monitor in the evolving market landscape.

Parallel to this trading activity, Plus Therapeutics has initiated patient treatments in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda), a groundbreaking therapy targeting leptomeningeal metastases (LM) linked to various primary solid tumors. This landmark trial builds on promising outcomes from a previous Phase 1 single-dose escalation study, which demonstrated REYOBIQ’s potential in addressing a pressing medical need where existing FDA-approved therapies are limited.

The ReSPECT-LM trial, conducted in line with the FDA’s Project Optimus, seeks to determine the optimal dosing regimen that balances safety and efficacy. Dr. Andrew Brenner, a noted neuro-oncology expert, expressed confidence in the trial’s prospects, anticipating rapid patient enrollment due to the encouraging preliminary results and the critical lack of effective treatment options for LM.

In prior research phases, REYOBIQ exhibited substantial promise, with over 80% of participants showing significant reductions in tumor cells in the cerebrospinal fluid and many surviving beyond one year post-treatment. The company plans to share further findings at the upcoming SNO/ASCO CNS Metastases Conference, aiming to transport advancements in treatment for LM into the spotlight.

Additionally, a substantial grant of $17.6 million from the Cancer Prevention & Research Institute highlights the collaborative effort toward enhancing cancer treatment solutions. Plus Therapeutics continues to drive innovation in targeted radiotherapy, bolstering hopes for improved patient outcomes in the challenging landscape of CNS cancers.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.